New-type R&D institutions inject strong growth momentum into Bodaweiye.

2020 2020 was destined to be an extraordinary year, and December 2020 is set to go down in the annals of Boda Weiye's remarkable development history.

12 On the 22nd, the Jilin Provincial Department of Science and Technology released Document No. [2020] 276, announcing the results of the 2020 accreditation for new R&D institutions in Jilin Province. Among the 11 organizations recognized, Bodaweiye was proudly listed as one of them.

As the primary entity hosting this new type of R&D institution—Jilin Boda Weiye Pharmaceutical Research Co., Ltd., a wholly-owned subsidiary of Jilin Boda Weiye Pharmaceutical Co., Ltd. and legally independent—our company is strategically located in the Jingyue Development Zone of Changchun. We boast extensive R&D experience, abundant external technical resources, and state-of-the-art R&D facilities, enabling us to deliver professional, precise, and comprehensive one-stop technical services—as well as eight specialized outsourcing services—to meet our clients' unique needs.

Since its establishment, the company has received numerous prestigious awards: National High-Tech Enterprise, Chairperson Unit of the Jilin Province "Chemical Drug Innovation Strategic Development Alliance," Outstanding Private Enterprise in Jilin Province, Jilin Province's Science and Technology Little Giant Enterprise, Collaborative Laboratory with Agilent Technologies (China) Co., Ltd., Jilin Province's Sole Pilot-Scale Engineering Center for Chemical Pharmaceutical Production, Jilin Province's Provincial-Level Enterprise Technology Center, Jilin Province's Science and Technology-Based Enterprise, Top 10 Innovative Enterprises in Jilin Province, and Joint Graduate Training Base with the School of Pharmacy at Yanbian University.

Currently, the company has 58 R&D personnel, over 90% of whom hold bachelor's degrees or higher, and more than 40% possess master's degrees or above. Additionally, the company has recruited 8 external expert consultants and hosts 6 technical professionals stationed at the Liaoyuan High-end Talent Workstation. The company also operates several dedicated project teams. With clear R&D strengths, since its establishment, the company has been committed to developing innovative chemical drugs and generic pharmaceuticals. To date, it has undertaken 31 national and provincial-level projects focused on technological breakthroughs and innovation成果转化 (technology transfer), resulting in 6 authorized invention patents and a total of over 40 R&D products.

As a new type of R&D institution characterized by diversified investment entities, an internationalized construction model, market-oriented operational mechanisms, and modernized management systems—with the capacity for sustainable development and collaborative innovation among industry, academia, and research—it serves as an open platform capable of integrating talent, technology, and R&D processes. This platform bridges connections between university research institutes, scientific institutions, and capital investors, ultimately facilitating the seamless alignment of research, industry, and financial resources.

The recognition of new types of R&D institutions that shoulder the important responsibilities of attracting talent and driving technological innovation. This will undoubtedly provide a strong impetus for the grand vision of Bo Da Weiye's future "14th Five-Year" development, paving the way for high-quality, sustainable growth as we dedicate ourselves to the noble cause of human health.

The future is worth looking forward to.

P.S.: Document from the Jilin Provincial Department of Science and Technology